Last reviewed · How we verify

ECTEINASCIDIN 743

Children's Oncology Group · Phase 1 active Small molecule Quality 60/100

ECTEINASCIDIN 743 is a Alkylating agent Small molecule drug developed by Children's Oncology Group. It is currently in Phase 1 development. Also known as: ET-743, NSC S648766, IND 50,286.

Binds to the minor groove of DNA, causing DNA strand breaks and disrupting DNA repair mechanisms and transcription.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036 —
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameECTEINASCIDIN 743
Also known asET-743, NSC S648766, IND 50,286
SponsorChildren's Oncology Group
Drug classAlkylating agent
ModalitySmall molecule
PhasePhase 1

Mechanism of action

Ecteinascidin 743 alkylates DNA at the N2 position of guanine in the minor groove, bending the helix toward the major groove. This triggers a cascade of events affecting DNA binding proteins and nucleotide excision repair pathways, ultimately leading to cell cycle arrest and apoptosis.

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ECTEINASCIDIN 743

What is ECTEINASCIDIN 743?

ECTEINASCIDIN 743 is a Alkylating agent drug developed by Children's Oncology Group.

How does ECTEINASCIDIN 743 work?

Binds to the minor groove of DNA, causing DNA strand breaks and disrupting DNA repair mechanisms and transcription.

Who makes ECTEINASCIDIN 743?

ECTEINASCIDIN 743 is developed by Children's Oncology Group (see full Children's Oncology Group pipeline at /company/children-s-oncology-group).

Is ECTEINASCIDIN 743 also known as anything else?

ECTEINASCIDIN 743 is also known as ET-743, NSC S648766, IND 50,286.

What drug class is ECTEINASCIDIN 743 in?

ECTEINASCIDIN 743 belongs to the Alkylating agent class. See all Alkylating agent drugs at /class/alkylating-agent.

What development phase is ECTEINASCIDIN 743 in?

ECTEINASCIDIN 743 is in Phase 1.

Related